Gedeon Richter announces availability of oral contraception Drovelis
Option contains new, synthetic version of naturally occurring oestrogen
Read More
Tag: Gedeon Richter
NICE draft final guidance for Gedeon Richter UK’s new uterine fibroids treatment
The therapy offers patients a convenient alternative to surgery or injections and can be administered at home
Read More
Marketing authorisation acquired for first and only transdermal contraceptive patch in UK
The Evra hormonal patch can be worn discreetly and according to Gedeon Richter UK Ltd, is over 99% effective at pregnancy prevention
Read More
UK launch for Vagirux
The drug is administered intravaginally as a local oestrogen therapy for treatment of vaginal atrophy due to oestrogen deficiency.
Read More
New transdermal HRT spray rolled out in the UK
Lenzetto, an estradiol spray, has been shown to reduce frequency and severity of hot flushes in post-menopausal women
Read More
Gedeon’s re-filed Neulasta biosimilar under EU review
European regulators have accepted a resubmission of Gedeon Richter’s biosimilar to Amgen’s Neulasta.
Read More
Allergan to file cariprazine for major depressive episodes
A late-stage study assessing Allergan/Gedeon Richter’s cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder has hit its primary target.
Read More
EU nod for Gedeon’s novel antipsychotic Reagila
European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
Read More
Allergan, Gedeon’s fibroid drug hits PhIII targets
Allergan and Gedeon Richter are gearing up to file ulipristal acetate in the US in the second half of this year, in the hope of securing approval for the first oral treatment option for women suffering from uterine fibroids in the country.
Read More
NICE backs non-surgical option for fibroids
Women with uterine fibroids stand to gain routine access to a non-surgical treatment on the National Health Service for the first time, after cost regulators endorsed Gedeon Richter’s once-daily pill Esmya as an option.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
